Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
CJC-1295 vs Tesamorelin
An educational, source-based comparison of CJC-1295 and Tesamorelin — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic analog of growth hormone-releasing hormone (GHRH). The non-DAC version has a short half-life that preserves pulsatile GH release, while DAC variants extend the half-life via albumin binding. Research focuses on stimulating endogenous GH and IGF-1 production via the pituitary.
- Endogenous GH pulse amplitude
- IGF-1 elevation
- Body composition in adult GH-deficient research
- Sleep architecture (slow-wave sleep)
- • GH-axis manipulation may affect glucose tolerance.
- • Banned in competitive sport (WADA).
- • Requires physician oversight in any therapeutic context.
A stabilized analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile endogenous GH and IGF-1 release. FDA-approved (Egrifta) for the reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy.
- Visceral adipose tissue reduction (approved)
- Cognitive function in older adults (research)
- NAFLD / hepatic fat (research)
- • FDA-approved only for HIV-associated lipodystrophy.
- • May affect glucose tolerance; monitor in at-risk patients.
- • Requires physician oversight.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| CJC-1295 | Sustained pharmacological GH activity in healthy adults via DAC technology | Journal of Clinical Endocrinology & Metabolism | 2006 | Established prolonged GH/IGF-1 elevation from single subcutaneous doses. |
| CJC-1295 | GHRH analogs and the GH-IGF-1 axis | Endocrine Reviews | 2011 | Mechanistic review of GHRH-analog pharmacology. |
| Tesamorelin | Tesamorelin for HIV-associated lipodystrophy | New England Journal of Medicine | 2007 | Phase 3 trials showing significant visceral fat reduction. |
| Tesamorelin | Tesamorelin and NAFLD in HIV | The Lancet HIV | 2019 | Reduced hepatic fat fraction in HIV-infected adults with NAFLD. |
Side-effect & safety grid
- GH-axis manipulation may affect glucose tolerance.
- Banned in competitive sport (WADA).
- Requires physician oversight in any therapeutic context.
- FDA-approved only for HIV-associated lipodystrophy.
- May affect glucose tolerance; monitor in at-risk patients.
- Requires physician oversight.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
CJC-1295 vs Tesamorelin — Key differences
- Class: CJC-1295 is classified as Growth Hormone Axis, while Tesamorelin is Growth Hormone Axis.
- Primary research focus: CJC-1295 — endogenous gh pulse amplitude; Tesamorelin — visceral adipose tissue reduction (approved).
- Tag: Growth hormone vs Body composition.